sparfloxacin has been researched along with ethambutol in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (38.46) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedi, AK; Chaturvedi, V; Gaikwad, A; Shukla, PK; Sinha, S; Srivastava, A; Srivastava, BS; Srivastava, R; Tewari, N; Tiwari, VK; Tripathi, RP | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ | 1 |
| Bollet, C; de Lamballerie, X; de Micco, P; Gevaudan, MJ; Mallet, MN; Sambuc, R | 1 |
| Cohen, Y; Grosset, J; Perronne, C; Pocidalo, JJ; Truffot-Pernot, C; Vildé, JL | 1 |
| Hadley, WK; Nassos, PS; Sanders, CA; Yajko, DM | 1 |
| Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
| Barbeau, P; Lapeyre, C; Leng, B; Maugein, J; Pellegrin, I; Pellegrin, JL | 1 |
| Kaur, D; Khuller, GK | 1 |
| Kaur, D; Khuller, GK; Verma, I | 1 |
| Boukriche, Y; Fantin, B; Masson, C; Zarrouk, V | 1 |
13 other study(ies) available for sparfloxacin and ethambutol
| Article | Year |
|---|---|
Synthesis of galactopyranosyl amino alcohols as a new class of antitubercular and antifungal agents.
Topics: Amino Alcohols; Animals; Antifungal Agents; Antitubercular Agents; Galactose; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.
Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin | 2010 |
[Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Mycobacterium; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Mycobacterium Infections; Opportunistic Infections; Quinolones; Rifabutin; Rifamycins | 1992 |
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Feasibility Studies; Female; Fluoroquinolones; Glucocorticoids; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mifepristone; Mycobacterium avium; Quinolones; Receptors, Glucocorticoid; Spleen; Time Factors; Tuberculosis | 1992 |
In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.
Topics: Acquired Immunodeficiency Syndrome; Anti-Infective Agents; Ciprofloxacin; Drug Synergism; Ethambutol; Fluoroquinolones; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Rifampin | 1990 |
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolones; Rifabutin | 1996 |
In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Interactions; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Mycobacterium avium; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Mycobacterium tuberculosis; Tuberculosis | 2001 |
Biochemical mechanism of combined effect of ethambutol and sparfloxacin against Mycobacterium smegmatis.
Topics: Anti-Infective Agents; Antitubercular Agents; Ethambutol; Fluoroquinolones; Membrane Lipids; Mycobacterium smegmatis; Phospholipids | 2001 |
[Efficacy of the sparfloxacin-ethambutol combination in a case of cerebral tuberculosis].
Topics: Adult; Anti-Infective Agents; Antitubercular Agents; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Rifampin; Tuberculosis, Central Nervous System | 2002 |